Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Monoaminergic anorectic agents].

K Fukagawa1, T Sakata

  • 11st Department of Internal Medicine, Oita Medical University, Idaiga-oka, Hazama-cho, Hazama-gun, Oita 879-5593, Japan. fukugawa@oita-med.ac.jp

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|December 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improvement of accommodation with anti-oxidant supplementation in visual display terminal users.

The journal of nutrition, health & aging·2012
Same author

Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis.

Allergy·2008
Same author

The differences of tear function and ocular surface findings in patients with atopic keratoconjunctivitis and vernal keratoconjunctivitis.

Allergy·2007
Same author

Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2006
Same author

Inflammatory cells in brush cytology samples correlate with the severity of corneal lesions in atopic keratoconjunctivitis.

The British journal of ophthalmology·2004
Same author

Treatment of atopic blepharitis by controlling eyelid skin water retention ability with ceramide gel application.

The British journal of ophthalmology·2003
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

Exploring novel anorectic agents, this study highlights L-Histizine, a histamine precursor, for appetite suppression and enhanced energy expenditure. It offers a promising, safer alternative to existing weight management drugs.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Context:

  • Anorectic agents modulate monoamines like dopamine and serotonin (5HT) to inhibit appetite.
  • Clinical use includes adrenergic and 5HT-receptor agonists, but some have severe side effects.
  • Histaminergic anorectics have not been clinically employed.

Purpose:

  • To review existing anorectic agents and their mechanisms.
  • To introduce L-Histizine as a potential histaminergic anorectic.
  • To explore the therapeutic potential of L-Histizine for obesity management.

Summary:

  • Catecholamines, dopamine, serotonin (5HT), and neuronal histamine are key anorectic neurotransmitters.
  • Existing anorectic drugs target adrenergic or 5HT receptors, with some agents like dexfenfluramine withdrawn due to cardiac issues.

Related Experiment Videos

  • L-Histizine, a histamine precursor, demonstrates efficacy in suppressing food intake, promoting lipolysis, and increasing energy expenditure in preclinical and human studies.
  • Unlike previous anorectics, L-Histizine offers a potential solution without the rebound weight gain phenomenon.

    • Impact:

    • L-Histizine presents a novel therapeutic strategy for obesity, potentially offering improved safety and efficacy.
    • This research may lead to the development of new, safer weight management drugs targeting the histaminergic system.
    • Understanding the role of histamine in appetite regulation opens new avenues for metabolic disorder research.